¬ü°ê¥[¦{¸t¦a¤ú­ô¥xÆW¦P¶m·|
San Diego Taiwanese Cultural Association
http://www.taiwancenter.com/sdtca/index.html
  2010 ¦~ 8 ¤ë

¤C¤ë¥÷°·±dÁ¿®y - °ü¬ìÂå¾Çªº·sµo®i
¼Ú¬K¬ü

³o½g¤å³¹¥»¸Ó¬O³o´Á¶m°TÁ`½s¿è°õµ§ªº¡A¤£¥©ªº¬O·í¤é¦o¥t¦³­«¥ô¦b¨­¡A»·©º¾ï°p¡A©Ò¥H¦A¤T¥mÀ{ªü¸q¥S´À¦o§ä¤H¥Nµ§¡C§Ú¾ã¤éµL¨Æ¦£ªº¦b¤¤¤ß¨«¹D¤W½Ä¨Ó®Ì¥h¡A±`¦³¤H¤£¬O³Q§Úªº«ü¦y±½¨ì´N¬O³Q§Úªº¸}¸òÛð¨ì¡F°ê°ò¥S¨C¦¸»·»·ªº¬Ý¨ì§Ú´Nª½ÄW·Ù¨®¡C¸Ü»¡¨º­Ó¬P´Á¤»Ãø±oªº¦­À\¦Y±o«Üº¡¨¬¡AÂù¨¬¦]¤£³ô­t²ü¦ÓÂÚ¶\¡A´N¤@¤U¤l³Qªü¸q¥S¦b¨«´Yùضe¨ì¡Cªü¸q¥S¤@¦V¥j¹D¼ö¸z¡A¹ï¤¤¤ß©M¦P¶mªº¤ä«ù¨S¤G¸Ü»¡¡C¹ïµÛ¨º¤@Áyµ½¨}¯ºÃC¡A¡ulearn to say no¡vªº©¾§i¡Aºà¨¥¤@¹ª¸£³£³Q§j¨ì¤ë«G¨ºÃä¥h¤F¡CµwµÛÀY¥Ö±µ¤U¥ô°È¡A³o¤@µ§´N¼È®Éµ¹°O¦b¬ü®Z©n©Mªü¸q¥Sªº±bï¤W¡C

±q¤p§Ú¹ï¦å´N¦³¬ÈÄß·P¡A¬Ý¨ì¥ô¦ó¶Ë¤f´N¥þ¨­µo³Â¡C¤jÂÎÅܤpÂÎ (¤£¦n·N«ä¦ÛºÙÀs)¡C¨à¤k­Ì¤p®É«ÜÃѽì¡A¤p¶Ë¤j¬}ªº³£¬O§äª¨ª¨¡A¤Ï¥¿³o¤@¤è­±¦Ñ¶ý¬O¡uª¯§p¤õ¨®¡A¨S¸ô¥Î¡v¡F¹ïÂåÃĤ譱ªº¾Ç²ß¤]¨S¤j­G¤f¡C¬Ý¨ì¿½Âå®vªºPower Point§Úº¡²´«_ª÷¬P¡A mamma mia¡A³o¨Ç¥~¬P±M¦³¦Wµü¬O½¼«}·N«ä¡H©Ò©¯²{¦bªººô¸ô¯u¬O¤Ó¯««i¤F¡A©~µMÅý§ÚªF«÷¦è´êªº§â¥D­nªº¤º®e´ê¤F¥X¨Ó (¨¯­W¤F§Ú³o¤@¹ï°ª«×ªñµøªº¡u©ú²¶¡v)¡C ¬°¤F°ß®£¼g¥X¤ÓÂ÷ÃЪº¿ù»~¡A¤]«ô°U¶ÀÂå®v®Õ¹ï¤F¤@¦¸¡C©Ò¥H¦b³oùØ¥i¥H«i´±ªºªþ¤@¥y¡u§K³dÁn©ú¡v¡G¡u¤å³¹¸g±M®aŲ©w¡F¦³°ÝÃD¡A¥h°Ý¶ÀÂå®v¡v¡C

Jack Hsiao¬Oªü¸q¥S (¿½«³¸q) ©M¨Î¤l©n¦b¬ü¤g¥Í¤gªøªºÄ_¨©¨à¤l¡A­·»D¤]¬O¶ÀÄm÷xÂå®v¥x»y¯Zªº±o·Nªù¥Í¡C³o¦^Å¥¤F¿½Âå®v¥þµ{ªº¥x»yºtÁ¿²×©ó¤F¸Ñ¬°¦ó¶ÀÂå®v¥u­n´£¨ì³o­Ó¡u¦n¾Ç¥Í¡v´N¬Ü¶}²´¯º¡FJackªº¥x»y¯u¥¿¬O¡uÆg¡v¡C¨º¨Ç¦b¥xÆWªø¤j¦Ó¤£·|»¡¥À»yªº¿»Á¦¤l¯u¸Ó¦½ÃC¡C¶¢¸Ü¤Ö»¡¡A¨¥Âk¥¿¶Ç¡A¥H¤U¬O¿½Âå®vªººtÁ¿ºK­n¡C

°ü²£¬ì

°ü²£¬ì·s°ò¦]¿z¬d§³®W¥H©¹³£­n16 - 20 weeks¤~¯à¦³¬ù40%ªº ±Ó·P©Ê¡A©Ò¥H¦³«Ü¦h¿ù»~¡C·sªºµo®i²Ä¤@¥¥´ÁÀˬd¥snuchal translucency¦b²Ä11-13¶g´N¥i¶i¦æ¡Cºî¦XÀˬdªº±Ó·P©Ê¥i¥H¹F¨ì93%-95%¡Cºî¦X¿z¬dÀ˵ø²Ä¤@©M²Ä¤G©u«×ªº«ü¼Ð¡A¥Hµû¦ô­·ÀI­ð¤óºî¦X¯g (Down syndrome) ©M18¤TÅéºî¦X¼x (trisomy 18)¡C³o­Ó´ú¸Õ¤]¥i¦bÃh¥¥´Áµû¦ô¶}©ñ¯«¸gºÞ·î§Î¡A¯á¬Wµõªº¥i¯à©Ê¡C³o¨Ç·sªº§Þ³N´î¤Ö³\¦h©â¦Ï¤ôªº¥²­n©Mµh­W¡Fºî¦X¿z¬dÀ˵ø ªºfalse negative ¤ñ¨Ò¬O7%¡C

¤l®cÀV©Ù¤ù (Pap Smear)

·sªºHPV (¤HÃþ¨ÅÀYª¬½F¯f¬r) ¿zÀË´M§ä°ª­·ÀIÃþ«¬16©M18¡F³o¨âºØÃþ«¬»P¤l®cÀVÀù¦³«Ü±K¤ÁªºÃö«Y¡C¾Ú¬ü°ê°ê¤ºªº²Î­p¡A¤l®cÀVÀùªº±wªÌ¸g´ú¸Õ¦³60-70% Åã¥ÜHPVÃþ«¬16¶§©Ê¤ÏÀ³¡A10-20%Åã¥ÜHPVÃþ«¬18¶§©Ê¤ÏÀ³¡C°²¦p¤l®cÀV©Ù¤ùµ²ªG¥¿±`¦A¥[¤W¨ÅÀYª¬½F¯f¬r¤ÏÀ³¬°³±©Ê¡A¤l®cÀVÀù¤T¦~¤ºªº­·ÀI¬O¤@¤d¤À¤§¤@¡C¤l®cÀV©Ù¤ù¿z¬d¶¡¹j®É¶¡¥i¼W¦Ü3¦~¦Ó¤£»Ý¨C¦~°µ¡C¦]¬°·s¿zÀ˧޳Nªºµo®i¡A¥Ø«e¤l®cÀVÀù¦º¤`¤H¼Æ¤v±q1950¦~¥Nªº¤­¸U¤H¤@¦~­°¤F90% ¦Ü¤­¤d¤H¤@¦~¡C

¤l®cÀV©Ù¤ù¥u¯à´ú¸Õ¤l®cÀVÀùªº­·ÀI¦Ó¤£¯à´ú¸Õ§Z±_Àù¡F§Z±_Àùªº¦­´Á¶EÂ_¬O¤Q¤À§xÃøªº¡C¤k©Ê¤@¯ë§Z±_Àùªº­·ÀI¬O 50 - 60 ¤H¤¤¦³¤@¤H (¤j¬ù1.6% - 2%)¡A­YBRCA1©MBRCA2¿zÀ˵²ªG¬°¶§©Ê«h­·ÀI´£°ª¦Ü25% - 50%¡A¦ýBRCA1©MBRCA2¿zÀ˶§©Ê¤ÏÀ³³q±`¤]¬O¨ì§Z±_Àù«á´Á¤~Åã²{¡C°²¦p²Ä¤@¯Å©M²Ä¤G¯Åªñ¿Ë¤¤¦³§Z±_Àùªº±w¨Ò¥[¤WBRCA¿zÀ˶§©Ê¡AÂå¥Í³q±`«Øij±N§Z±_®³±¼¡C

¨Å©ÐÀù»P§Z±_Àù

§Z±_Àù«Ü¤Ö¯S®í¯gª¬¡A©Ò¥H±wªÌ©MÂå¥Í±`©¿µø§Z±_Àùªº¥i¯à©Ê¡F³Ì³q±`ªº¯gª¬¬O¡G
1. ®e©öı±o¸¡µÈ
2. ¦çªA¹ê»Ú¤W¤£ºò¦ý¬ï¦ç³£Ä±±oºò¡C

¤@¯ë¨Ó»¡ªF¤è¤H±w¨ÅÀùªº­·ÀI¸û§C¡A¤×¨ä¬O¦í¦b¤é¥»ªº¤é¥»¤k©Ê¡F¦ý¬O³o¸òÀô¹Ò¦³«Ü¤jªºÃö«Y¡C¤é¥»¤H­Y©~¦í©ó¬ü°ê«h±w¨ÅÀùªº­·ÀI©M¬ü°ê¤H¤@¼Ë¡C¤@¯ë¬ü°ê¤k©Ê¥|¤Q·³¥H¤W¤~¦³¨ÅÀùªº­·ÀI¡A¦Ó¥xÆW¤k©Ê¦³¸û¦~»´¡A¦b¤T¤Q·³¥ª¥k´Nù±w¨ÅÀùªº¡C ªñ¿Ë¤¤­Y¦³¼Æ­Ó¨ÅÀù¯f¨Ò«Øij¨C¦~°µ¤@¦¸mammogram¡A¨C¹j¤@¦~°µ¤@¦¸MRI¡C

¨Å©ÐÀù»P§Z±_Àù¦³¬YºØÃö³s¡F¨Å©ÐÀùªº±wªÌ­YBRCA gene ¿zÀ˶§©Ê¡A»Û¿E¯À¨üÅé§e¶§©Ê¡A³q±`§Z±_Àùªº­·ÀI«Ü°ª¡CÂå¥Í·|«Øij¦b¨ÅÀùªvÀø§¹¥þ¤§«á±N§Z±_®³±¼¡C

§ó¦~´Á

²üº¸»X»Û¿E¯À´À¥NÀøªk¦³«Ü¦hª§Ä³¡A¦]¬°¦¹ÃþÃľ¯¦³¼W¥[¨ÅÀùªº­·ÀI¡CThe American College of OBGYNªº«Øij¬O¡uªA¥Î³Ì¤Ö»Ý­n¶q¡A ³Ìµu´Á¡v¡C¤@¯ë¨ÓÁ¿¡A ªA¥Î²üº¸»X»Û¿E¯ÀÃľ¯ªº­ì¦]¬O¨¾¤î¼é¼öªº¤£¾A¡C¿½Âå®v¹ï¥Ø«e¦³ªA¥Î»Û¿E¯ÀÃĪ«ªÌªº«Øij¬O¶}©l´î¤ÖÃĶq¡A­Y¨S¦³¼W¥[¤£¾A«h¥iÄ~Äò´î¶q¡F¥tªÌ¡A¥i¥H°±¤î¨Ï¥Î¨â¬P´Á¡A­Y¨S¦³·Pı«Ü¤jªº®t²§¡A«h¥i°±¥Î¡F°²¦p¬°¤F¨¾¤î°©Àf²¨ÃP¦ÓªA¥Î¡A¥i¥H½ÐÂå®v¥t¥~¶}ÃĤè¡C»Û¿E¯À¥i¯à·|¦³¨Ç·L¨ä¥L¼W¥[¤k©Ê²üº¸»Xªº¦n³B¡F¦ý³o¨Ç¦n³B»P¨ÅÀù­·ÀI´£°ªªºÃa³B¨Ó¤ñ¸û¡A¬O¤£­È±oªº¡C

Bioidentical hormone therapy - ¡ubioidentical¿E¯ÀÀøªk¡v¬O¸g±`³Q¥Î¨Ó´y­zÃĪ«§t¦³»Û¿E¯À¡A¥¥¿E¯À©Î¨ä¥L¿E¯ÀªºÃĪ«¡C¥«­±¤W¦³³\¦h¬ü°ê FDA§å­ãªº
bioidentical¿E¯À³B¤èÃÄ¡F¦ý¬O¥Ø«e©|¨S¦³¨¬°÷¬ì¾ÇÃÒ¾Ú¤ä«ù³è²G©M¦å²G¿E¯À¤ô¥­ªº´ú¸Õ¥i¥Î¨Ó©w¨î³B¤è¡C¬ü°ê­¹«~©MÃĪ«ºÞ²z§½ (FDA) ©M¨ä¥L¬ì¾Ç²Õ´ĵ§i°ü¤k³oÃþ³B¤è²£«~¨ã¦³¼ç¦bªº¦M®`¡F¥_¬ü§ó¦~´Á¨ó·| (NAMS) ¤ä«ù³oºØ¥ß³õ¡C

¦Ü©ó¤¤ÃÄÃĤè©M©Ò¿×¶À¨§³J¥Õ½èªºªvÀø¡A¨S¦³¥¿¦¡ªº¬ã¨s³ø§i«ÜÃøÂ_©w¯u¥¿ªº®Ä¥Î¡F¶¼­¹ªºÀô¹Ò­Ë¥i¥H½T©w©M¯e¯f­·ÀI®§®§¬ÛÃö¡C

Á×¥¥

¡i¤fªAÁ×¥¥ÃÄ¡j
¬ü°ê³Ì¦nÁÈ¿úªºÃĬOÁ×¥¥ÃÄ¡C³Ì·sFDA§å·ÇªºÁ×¥¥ÃÄ¥i¥H¤T­Ó¤ë¬Æ¦Ü¤@¦~¤~¦³¤@¦¸¤ë¸g¡C¨S¦³¤@ºØÁ×¥¥ÃĬO³Ì¦nªº¡A­Ó¤HÅé½è¤£¦P¹ïÃĪ«ªº¤ÏÀ³¥ç¦³²§¡C¤@¯ë¨Ó»¡¡A¯à«ö®ÉªA¥Î¦Ó¹ï§A°Æ§@¥Î³Ì¤Öªº´N¬O³Ì¾A¦XªºÃĪ«¡C

¡i´Ó¤J¦¡Á×¥¥ªk¡j
¦]´¶©ÔR( ImplanonR)©MNorplant³£¬O¤@ºØ°ü¤k¸`¨|Ãþ«¬¡C¦]´¶©ÔR§t¦³¿E¯ÀºÙ¬° etonogestrel¡A¬O¤@­Ó¸m©ó¥Ö½§¤âÁu¤Uªº¶ì®Æ´Î¡A¤j¤p¦p¤@­Ó¤õ®ã±ì¡F§A¥i¥H¨Ï¥Î³æ¤@¦]´¶©ÔR±ìªø¹F 3¦~¡C¥Ñ©ó¦]´¶©ÔR¤£¥]§t»Û¿E¯À¡A§Y¨Ï§A¤£¯à¨Ï¥Î»Û¿E¯À¡AÂåÀø«O°·¤]¥i¯à·|«Øij¨Ï¥Î¦]´¶©ÔR¡C

¡iMirena - IUD¡j
Mirena¬O¤@ºØ§t¶ÀÅé¿E¯À (progestin) ªº¤p«¬Å餺Á×¥¥¸Ë¸m¡A¦b¤­¦~¤§¤º¦³99.9% ¨¾¤îÃh¥¥ªº®Ä¯à¡CMirena ªº¸Ë¸m¬O¥Ñ³±¹D´¡¤J¡A³q¹L¤l®cÀV´Ó¤J¤l®c¡C

¡iNuvaRing¡j
NuvaRing ¬O¤@ºØ¿E¯ÀÁ×¥¥³±¹DÀô¡C¥Ø«e®Ö©wNuvaRingªº¤è®×«ü©w´¡¤J¨ì³±¹DÀô¤T­Ó¬P´Á«á­n¨ú¥X¤@­Ó¬P´Á¡F¦b¥h°£´Á¶¡¡A¥Î¤á·|ÅéÅç¨ì¤ë¸g´Á¡C

¡iEssure¡j
¥H©¹°ü¤k­Y¤£­n¦A¥Í¨|¡A°ß¤@¤èªk¬O¹ê¬Iµ²²Ï¿é§ZºÞªº¶}¤M¤â³N¡F·sªº§Þ³N¥i¨Ï°ü¤k¹F¨ìµ´¨|ªº¥Ø¼Ð¦Ó¤£»Ý°Ê¤M¡CEssure ¬O¤@­Ó¥Ã¤[©Êªºµ´¨|¤â³N¡AMicro-inserts¥Ñ¾ÉºÞ¤Þ¾É±q³±¹D³q¹L¤l®cÀV©M¤l®c©ñ¨ì¿é§ZºÞ¤¤¡F¤â³N«á¥Ã»·µLªk¦A¥Í¨|¡C

Adiana »PEssure «D±`Ãþ¦ü¡A¦ýAdiana ¬O¶ì½¦»s«~¨S¦³ª÷Äݦ¨¥÷¡FAdiana©ñ¤J«á¥²¶·¨Ï¥Î¥t¤@ºØ§Î¦¡ªº¥Í¨|±±¨î3­Ó¤ëÅý·sªº²Õ´¥Íªø¡A²×¦Óªý¶ë±zªº¿é§ZºÞ¡F 3­Ó¤ë«á»Ý­n°õ¦æ¤@­Ó¯S®íªº´ú¸Õ¥H½T»{±zªººÞ§¹¥þªý¶ë¡C

°ü²£¬ì¤â³N

²£¬ì¤â³N·í«e¦³¤@¨Ç¹ï¨­Åé¶Ë®`¸û§Cªº¤â³N¿ï¾Ü¡G

¡i¤l®c¤º½¤ªº¿N»k (Endometrial ablation) ¡j
¤l®c¤º½¤®ø¿Ä³N¬O¤@ºØÂåÀøµ{§Ç¡A¥Î¨Ó§R°£(®ø¿Ä)©Î¯}Ãa¤l®c¤º½¤¡C³oºØ§Þ³N¸g±`¬I¥Î©ó¸g´Á¥X¦å¹L¦h©Î¤ë¸g¶g´Á¹Lªø¡A¦ý¤£ ¯à©Î¤£Ä@±µ¨ü¤l®c¤Á°£³Nªº°ü¤k¡C¥Ø«e³Ì´¶¹Mªº¤TºØµ{§Ç¬ONovasure¡AHTA¡AThermachoice¡C³o¤TºØµ{§Ç³£¬O·í¤Ñ¥i¦^®aªºout-patient¤â³N¡C

¡iªvÀø¤l®c¦Ù½F¡j
ªvÀø¤l®c¦Ù½F¸û«O¦uªº¿ï¾Ü¦³¤l®c¦Ù½F­ç°£³N (Myomectomy) ©M¤l®c°Ê¯ß®ê¶ë(Uterine artery embolization)¡F¸û·sªº¦³¸¡µÄÃè¤â³Nªk (Laparoscopy) ©M¾÷¾¹¤H¤â³N (Robotic surgery)¡C«O¦uªº¤l®c¦Ù½F­ç°£³N (Myomectomy) ¨Ï¥Î®cµÄÃè (Hysteroscopy) ©M¤À¸Hµ{§Ç(morcellation)¡C·sªº§Þ³N¦p¸¡µÄÃè¤â³Nªk©M¾÷¾¹¤H¤â³N¥i¥H¸g¥Ñ«Ü¤pªº¤Á¤f¡A¹B¥Î·s«¬Äá¼v¾¹¨ã±NÅ餺¾¹©x¼v¹³©ñ¤jÅã¥Ü¦b¹qµø¤W¡AÂå¥Í«h¥Î¾÷¾¹¾ÞÁa¤â³Nªº¹Lµ{¥H¥N´À¶Ç²Îªº¶}¤M¤â³N¡F¤â³N¹Lµ{¤×¦p¦bª±¹q¤l¹CÀ¸¤@¯ë¡C

»¡¨ì³o¸Ì¡A¿½Âå®v¤£§Ñ«Õ¤F¥L¤÷¥Àªü¸q¥S·A¤@Àq¡Fªü¸q¥S·A¦b¿½Âå®v¤p®É±`»¡¥L®ö¶O¤Ó¦h®É¶¡¦b¹qª±¤W¡A ±E¤£ª¾¿½Âå®vªº¹qª±½m±o¥LÂù¤â¦n¤u¤Ò¡A²{¦b¾a³o¤u¤Ò¡u¨«¬õ¡v¡FÂå®v­Ì³£³ßÅw©M¥L¦X§@¦]¬°¥L¦³¤@¬yªº¡u¥©¤âÃÀ¡v¡C©^ÄU½Ñ¦ìªü¤½ªüÀ¨¬Ý¨ì®]¨à¤k½m¡u¹qª±¥\¤Ò¡v¤£­n¦A¡u¸H¸H©À¡v¡A¬Û¤Ïªº¥i¥H¥[±j¹ªÀy (¥i±¤¡A¨à¤k¤j·§¨Ó¤£¤Î°V½m¤F)¡A´Á«Ý¥L¤é¦³¦¨¤]¥i¥H¥Î¤Q«ü¯«¥\¡u±´¤j¿ú¡v¡C